{"Symbol": "ACRS", "AssetType": "Common Stock", "Name": "Aclaris Therapeutics Inc", "Description": "Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.", "CIK": "1557746", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "701 LEE ROAD, WAYNE, PA, UNITED STATES, 19087", "OfficialSite": "https://www.aclaristx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "345621000", "EBITDA": "-65738000", "PERatio": "None", "PEGRatio": "-0.13", "BookValue": "1.109", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.58", "RevenuePerShareTTM": "0.136", "ProfitMargin": "0", "OperatingMarginTTM": "-5.17", "ReturnOnAssetsTTM": "-0.23", "ReturnOnEquityTTM": "-1.132", "RevenueTTM": "15742000", "GrossProfitTTM": "-43398000", "DilutedEPSTTM": "-1.58", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.241", "AnalystTargetPrice": "8", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "6", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "21.96", "PriceToBookRatio": "2.878", "EVToRevenue": "14.42", "EVToEBITDA": "0.279", "Beta": "0.865", "52WeekHigh": "4.89", "52WeekLow": "1.05", "50DayMovingAverage": "3.243", "200DayMovingAverage": "2.162", "SharesOutstanding": "108345000", "SharesFloat": "82010000", "PercentInsiders": "2.957", "PercentInstitutions": "79.277", "DividendDate": "None", "ExDividendDate": "None"}